Cogent Biosciences, Inc.
bezuclastinib
NonAdvanced Systemic Mastocytosis (NonAdvSM)
Resolved
218days ago
Phase 2 readout · Dec 1, 2025
What's at stake
Phase 2 trial results for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) are due Dec 1, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In December 2025, announced topline results from the APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM), APEX is a registration-directed, global, open-label trial evaluating bezuclastinib in patients”